This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murray, C. K. Articles by Byrd, J. C. Search for Related Content PubMed PubMed Citation Articles by Murray, C. K. Articles by Byrd, J. C.

CD56 Expression in Acute Promyelocytic Leukemia: A Possible Indicator of Poor Treatment Outcome?

From Walter Reed Army Medical Center, Washington, DC; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Montefiore/Albert Einstein Cancer Center, Bronx, NY; Eastern Cooperative Oncology Group, Brookline, MA; and Duke University Medical Center, Durham, NC.

Address reprint requests to John C. Byrd, MD, Hematology-Oncology Service, Ward 78, Walter Reed Army Medical Center, Washington, DC 20307; Email john_c.byrd{at}wrammaa.chcs .amedd.army.mil

PURPOSE: Blast expression of CD56 is frequent in patients with t(8;21)(q22;q22) acute myeloid leukemia and is associated with an inferior outcome. The expression of CD56 has rarely been reported in acute promyelocytic leukemia (APL) and has not been clinically characterized. Therefore, we examined the prognostic significance of CD56 expression in APL.

PATIENTS AND METHODS: We identified all reported cases of CD56⁺ APL in the medical literature and collected clinical, biologic, and therapeutic details.

RESULTS: Data were obtained for 12 patients with CD56⁺ APL (> 20% blast expression of CD56), including four cases from a single institution with a total of 42 APL patients. All of the CD56⁺ APL patients had documented cytogenetic presence of t(15;17), and of the nine reported isotypes, eight (89%) were S-isoform. Only six CD56⁺ patients (50%) attained complete remission (CR); the other six individuals died within 35 days of presentation. Of the six patients who attained a CR, three (50%) relapsed at 111, 121, and 155 weeks, whereas three remained in continuous CR at 19, 90, and 109 weeks. Comparison of the control CD56^- to CD56⁺ APL patients demonstrated that the latter group had a significantly lower fibrinogen level (P = .007), and among patients for whom data were available, there was a higher frequency of the S-isoform (P = .006). Additionally, the CR rate (50% v 84%, P = .025) and overall median survival (5 v 232 weeks; P = .019) were significantly inferior for CD56⁺ APL patients.

CONCLUSION: CD56⁺ acute promyelocytic leukemia is infrequent, seems to occur more frequently with the S-isoform subtype, and may be associated with a lower CR rate and inferior overall survival.

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the US Army or Department of Defense.

This article has been cited by other articles:

				C. Assaf, S. Gellrich, S. Whittaker, A. Robson, L. Cerroni, C. Massone, H. Kerl, C. Rose, A. Chott, S. Chimenti, et al. CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer J. Clin. Pathol., September 1, 2007; 60(9): 981 - 989. [Abstract] [Full Text] [PDF]

				M. S. Tallman, J. W. Andersen, C. A. Schiffer, F. R. Appelbaum, J. H. Feusner, W. G. Woods, A. Ogden, H. Weinstein, L. Shepherd, C. Willman, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol Blood, December 15, 2002; 100(13): 4298 - 4302. [Abstract] [Full Text] [PDF]

				M. S. Tallman, C. Nabhan, J. H. Feusner, and J. M. Rowe Acute promyelocytic leukemia: evolving therapeutic strategies Blood, February 1, 2002; 99(3): 759 - 767. [Abstract] [Full Text] [PDF]

				B. Cassinat, S. Chevret, F. Zassadowski, N. Balitrand, I. Guillemot, M.-L. Menot, L. Degos, P. Fenaux, and C. Chomienne In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome Blood, November 1, 2001; 98(9): 2862 - 2864. [Abstract] [Full Text] [PDF]

				R. Suzuki, Y. Kagami, K. Takeuchi, M. Kami, M. Okamoto, R. Ichinohasama, N. Mori, M. Kojima, T. Yoshino, H. Yamabe, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype Blood, November 1, 2000; 96(9): 2993 - 3000. [Abstract] [Full Text] [PDF]

				D. Sainty, V. Liso, A. Cantu-Rajnoldi, D. Head, M.-J. Mozziconacci, C. Arnoulet, L. Benattar, S. Fenu, M. Mancini, E. Duchayne, et al. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements Blood, August 15, 2000; 96(4): 1287 - 1296. [Abstract] [Full Text] [PDF]

				F. Ferrara, F. Morabito, B. Martino, G. Specchia, V. Liso, F. Nobile, P. Boccuni, R. Di Noto, F. Pane, M. Annunziata, et al. CD56 Expression Is an Indicator of Poor Clinical Outcome in Patients With Acute Promyelocytic Leukemia Treated With Simultaneous All-Trans-Retinoic Acid and Chemotherapy J. Clin. Oncol., March 13, 2000; 18(6): 1295 - 1300. [Abstract] [Full Text] [PDF]

				J. L. Slack, C. L. Willman, J. W. Andersen, Y.-P. Li, D. S. Viswanatha, C. D. Bloomfield, M. S. Tallman, and R. E. Gallagher Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from Intergroup protocol 0129 Blood, January 15, 2000; 95(2): 398 - 403. [Abstract] [Full Text] [PDF]